Amazentis SA   Report issue

For profit Phase 1
Founded: Lausanne Switzerland (2007)

Organization Overview

First Clinical Trial
2016
NCT02655393
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Amazentis SA

Active Ingredients

Drugs in Phase 1 Trials (1)

amaz-02 (3 trials)

Drugs in Other Trials (2)

pomegranate (3 trials)

urolithin a (5 trials)

Indications

Overview

  • Highest Phase: Phase 1
  • # of Trials: 9
  • # of Trial APIs: 3